7-硝基-3,4-二氢-2H-1,4-苯并噁嗪 | 120711-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 7-硝基-3,4-二氢-2H-1,4-苯并噁嗪
• 中文别名: 7-硝基-3,4-二氢-2H-1,4-苯并异噁嗪；7-硝基-3,4-二氢苯并[1,4]恶嗪；7-硝基-3,4-二氢-2H-1,4-苯并恶；7-硝基-3,4-二氢-2H-1,4-苯并恶嗪
• 英文名称: 7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
• 英文别名: 3,4-dihydro-7-nitro-2H-1,4-benzoxazine；7-Nitro-3,4-dihydro-2H-1,4-benzoxazine
• CAS: 120711-81-1
• 化学式: C₈H₈N₂O₃
• mdl: MFCD11603433
• 分子量: 180.163
• InChiKey: YKCFDUNYLMTXFC-UHFFFAOYSA-N

物化性质

• 熔点：
  187-188°
• 沸点：
  341.6±42.0 °C(Predicted)
• 密度：
  1.332±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  67.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319
• 储存条件：
  2-8°C

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 7-Nitro-3,4-Dihydro-2H-1,4-Benzoxazine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 180,16 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
7-Nitro-3,4-Dihydro-2H-1,4-Benzoxazine
Acute Tox. 3; H301 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
7-Nitro-3,4-Dihydro-2H-1,4-Benzoxazine
T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (7-Nitro-3,4-Dihydro-2H-1,4-Benzoxazine)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (7-Nitro-3,4-Dihydro-2H-1,4-Benzoxazine)
IATA: Toxic solid, organic, n.o.s. (7-Nitro-3,4-Dihydro-2H-1,4-Benzoxazine)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H301 Toxic if swallowed.
Full text of R-phrases referred to under sections 2 and 3
T Toxic
R25 Toxic if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  7-硝基-3,4-二氢-2H-1,4-苯并噁嗪 在 aluminum oxide 、 铁粉 、 sodium hydride 、 氯化铵 、 三乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 56.83h， 生成 (S)-2-chloro-N-(4-(2-((5-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)pentyl)amino)-2-oxoethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide
  参考文献：
  名称：

  发现用于靶向蛋白质降解应用的共价 FEM1B Recruiter

  摘要：

  蛋白水解靶向嵌合体 (PROTAC) 是一种异双功能化合物，由与 E3 连接酶募集剂连接的蛋白靶向配体组成，已成为靶向蛋白降解 (TPD) 的强大治疗方式。尽管 TPD 方法在药物发现中很受欢迎，但只有少数 E3 连接酶招募人员可用于人类细胞中存在的 >600 E3 连接酶。在这里，我们发现了一种半胱氨酸反应性共价配体 EN106，其靶向 FEM1B，这是一种最近发现的 E3 连接酶，是细胞对还原应激反应的关键组成部分。通过针对 FEM1B 中的 C186，EN106 破坏了对 FEM1B 关键还原应力基质 FNIP1 的识别。我们通过证明将 EN106 连接到 BET 溴结构域抑制剂 JQ1 或激酶抑制剂达沙替尼的 PROTAC 分别导致 BRD4 和 BCR-ABL 的降解，进一步确定 EN106 可用作 TPD 应用中 FEM1B 的共价招募剂。我们的研究展示了一种针对天然 E3 连

  DOI：

  10.1021/jacs.1c03980
• 作为产物：
  描述：

  2-氨基-5-硝基苯酚 在 硼烷四氢呋喃络合物 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.5h， 生成 7-硝基-3,4-二氢-2H-1,4-苯并噁嗪
  参考文献：
  名称：

  氨基荧光素将萤火虫荧光素酶的生物发光扩展到近红外区域，可以作为首选底物过荧光素

  摘要：

  萤火虫荧光素酶腺苷酸化和氧化 d-荧光素以化学方式产生可见光，广泛用于生物测定和成像。在这里，我们表明荧光素酶和荧光素都可以重新设计以扩展这种发光反应的范围。d-荧光素可以被合成荧光素类似物替代，在表达荧光素酶的活细胞中，近红外光子通量是 d-荧光素通量的 10 倍以上。萤火虫荧光素酶可以突变以接受和利用在活细胞和裂解细胞中都具有高活性的刚性氨基荧光素，但其选择性比天然荧光素酶底物高 10 000 倍。因此，这些新的荧光素类似物为生物发光报告基因的扩展家族铺平了道路。

  DOI：

  10.1021/ja505795s
• 作为试剂：
  描述：

  2,3-dihydro-4-(1-methylethyl)-1,4-benzoxazin-7-yl isothiocyanate 、 甲基肼 以 乙醇 、 7-硝基-3,4-二氢-2H-1,4-苯并噁嗪 为溶剂， 生成 4-[2,3-dihydro-4-(1-methylethyl)-1,4-benzoxazin-7-yl]-2-methyl-3-thiosemicarbazide
  参考文献：
  名称：

  Herbicidal substituted-phenyl-1,2,4-triazol-5(1H)-thiones and -ones

  摘要：

  本申请揭示了除草取代苯基-1,2,4-三唑-5(1H)-硫醚和酮，包含这些化合物的除草组合物，其制备方法，以及通过将除草组合物在期望控制的地点进行种前和/或种后施用来控制不受欢迎的植物生长的方法。这些除草化合物是以下公式的化合物 其中Ar从中选择 R从卤代烷基中选择；R.sup.1从烷基中选择；R.sup.2从氢，卤素，烷基卤代氧基，卤代烷基，烷氧基，炔基，烷基硫醚，硝基，氨基和氰基中选择；R.sup.3从氢，卤素，烷基，烷氧基，炔基，硝基，氨基，单取代或双取代氨基，氰基和羟基中选择；R.sup.4从氢，卤素，烷基，烯基，炔基，三甲基硅烯基，氰基，硝基，氨基，卤代烷基，单取代或双取代氨基，四烷基铵盐，羟基，烷氧基，苯氧基，苄基，苄氧基，烷基硫醚，烷基磺酰基，烷基羰基，苯基羰基，吡咯啉基，哌啶基，吗啉基，烷基硫醚氧基，烯氧基，烷基烯氧基，卤代烯氧基，烯丙氧基，环烷基烷氧基，环烷氧基和卤代烷氧基中选择；R.sup.5从氢，卤素，烷基，烷氧基，卤代烷氧基和卤代烷基中选择；或R.sup.3和R.sup.4或R.sup.4和R.sup.5可以连接形成--OCH.sub.2 O--，--CH.sub.2 C(CH.sub.3).sub.2 O--，--OC(CH.sub.3 (CH.sub.2 CH.sub.3)O--，--N(CH.sub.2 CH.sub.3)CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.3)--，--OCH.sub.2 CH.sub.2 N[CH(CH.sub.3).sub.2 ]--，--OCH.sub.2 CH.sub.2 O--，--OC(CH.sub.3).sub.2 O--，--C(O)C(CH.sub.3).sub.2 O--或--CH.sub.2 CH.sub.2 CH.sub.2 O--；R.sup.6从氢，卤素，烷基和烷基硫醚中选择；R.sup.7和R.sup.8是烷基，不一定相同；W从S和O中选择。

  公开号：

  US05108486A1

文献信息

• 预防和治疗慢性疼痛药物的胍类化合物
  申请人：绍兴从零医药科技有限公司

  公开号：CN111548313A

  公开（公告）日：2020-08-18

  本发明涉及通式(Ⅰ)所示的涉及作为防治慢性疼痛疾病的胍类化合物、其药学上可接受的盐、其前体药物、其溶剂化物、氘代物或其立体异构体，其中R1、R2、R3、R4、R5、Ar1、Ar2、p和q的定义同说明书中所述定义；本发明还涉及所述化合物的制备方法，含有所述化合物的药物组合物和药物制剂，以及所述化合物在用于预防或治疗哺乳动物治疗带状疱疹疼，三叉神经疼，偏头痛等神经病理性疼痛，胰腺炎，关节炎疼等在内的急慢性炎性疼痛等疼痛症状和疼痛引起的及其他因素引起的睡眠失调等疾病的药物中的应用。
• Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
  申请人：Kelly G. Michael

  公开号：US20060194801A1

  公开（公告）日：2006-08-31

  Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

  抱歉，我无法直接提供翻译结果。但我可以帮助您翻译这段文字。这段文字的中文翻译如下： 揭示了具有以下表示的公式的化合物： 这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如疼痛、炎症、创伤性损伤等。
• [EN] FEM1B PROTEIN BINDING AGENTS AND USES THEREOF<br/>[FR] AGENTS SE LIANT À LA PROTÉINE FEM1B ET UTILISATIONS ASSOCIÉES
  申请人：UNIV CALIFORNIA

  公开号：WO2021183431A1

  公开（公告）日：2021-09-16

  Disclosed herein, inter alia, are compounds for binding FEMIB protein and uses thereof. In an aspect, provided herein is a pharmaceutical composition including a compound as described herein and a pharmaceutically acceptable excipient.

  本文披露了用于结合FEMIB蛋白的化合物及其用途。在一个方面，本文提供了一种包括本文描述的化合物和药用可接受的赋形剂的药物组合物。
• Androgen receptor modulator compounds and methods
  申请人：Ligand Pharmaceuticals, Inc.

  公开号：US06462038B1

  公开（公告）日：2002-10-08

  Compounds, pharmaceutical compositions, and methods for modulating processes mediated by steroid receptors. In particular, preparation and methods of use of non-steroidal compounds and compositions that are agonists, partial agonists, and antagonists for the androgen receptor (AR) are described. Further, described are the methods of making and use of critical intermediates including a stereoselective synthetic route to intermediates for the AR modulators.

  化合物、药物组合物和调节类固醇受体介导过程的方法。具体描述了非类固醇化合物和组合物的制备和使用方法，这些化合物和组合物是雄激素受体（AR）的激动剂、部分激动剂和拮抗剂。此外，还描述了制备和使用关键中间体的方法，包括用于AR调节剂的立体选择性合成路线。
• BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY
  申请人：Ramnauth Jailall

  公开号：US20100009975A1

  公开（公告）日：2010-01-14

  The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.

  本发明涉及抑制一氧化氮合酶（NOS）的苯并噁嗪，苯并噻嗪和相关化合物，特别是那些选择性地抑制神经一氧化氮合酶（nNOS）而不是其他NOS同工型的化合物。本发明的NOS抑制剂，单独或与其他药用活性剂结合使用，可用于治疗或预防各种医疗状况。